Business 4 min read By Bethany Hadley
Wendy’s rejects Peltz’s $1.4 billion buyout offer as undervaluing the chain
Wendy’s board has publicly turned down a $1.4 billion takeover bid from billionaire Nelson Peltz’s investment firm Trian, calling the offer substantially undervalued and adopting a poison pill defence against it.
Wendy’s has publicly rejected a $1.4 billion buyout offer from billionaire investor Nelson Peltz, with the fast food chain’s board saying the bid substantially undervalues the company. The offer comes through Trian, Peltz’s investment firm, and the board has responded by adopting a poison pill defence designed to block any large accumulation of the company’s shares without its approval.
The board argues that the bid fails to reflect Wendy’s long-term potential. The rejection comes at a difficult moment for the chain, which has reported seven consecutive quarters of falling same-store sales. Those declines have put pressure on the company as it competes in a crowded fast food market, and they form the backdrop to the current dispute over its valuation. Same-store sales, which measure revenue at restaurants open at least a year, are closely watched by investors as a gauge of a chain’s underlying health, which is why the run of declines has become central to the debate.
Peltz has a long association with Wendy’s. One report credits him with having previously helped save the company, a history that adds a personal dimension to the current offer. Trian’s proposal now places the future of the chain at the centre of a boardroom standoff, with the board and the would-be buyer taking opposing views on what the business is worth. The gap between the two positions is the core of the dispute: the offer values the company at $1.4 billion, and the board considers that figure too low to reflect what it sees as the chain’s prospects beyond its current difficulties.
Not everyone agrees with the board’s decision. An industry expert has described the rejection as a mistake, suggesting that the offer deserves more serious consideration given the chain’s recent performance. The expert’s view adds to the debate over whether the board is protecting shareholder value or resisting a deal that could benefit investors. The question is a familiar one in takeover fights, where directors must weigh the price on the table against their duty to shareholders and their own assessment of the company’s future.
The poison pill is a standard defensive tool in such situations. By making it costly for any single investor to build a large stake without board approval, it gives directors time and leverage to assess an unsolicited bid and to seek alternatives or better terms. Its presence signals that the board is not prepared to engage on the current terms, at least for now.
Several questions remain open. It is not yet clear whether Peltz will raise his offer in response to the rejection. Nor is it known whether Wendy’s shareholders will back the board’s position, a key factor in how the standoff is resolved. The timeline for the poison pill is also unconfirmed, meaning the company’s defensive measure could remain in place for an uncertain period. Each of these variables could shift the balance of the contest in the weeks ahead.
For now, the outcome of the bid depends on the next moves by Trian and on how investors respond to the board’s stance. Wendy’s has made clear that it does not consider the current proposal acceptable, and the company’s shareholders will be watching closely as the dispute develops.
Source: forbes.com
12
